Physician profile
Thomas Holthus
NPI 1124083498
$1,101.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $86.93 · 2021: $44.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $344.03 | 2019-2021 | |
| Novo Nordisk INC | $335.54 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.84 | 2019 | |
| Amgen INC. | $76.82 | 2019 | |
| Lilly USA, LLC | $70.71 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $46.88 | 2019-2020 | |
| Mylan Specialty L.P. | $37.90 | 2019 | |
| Glaxosmithkline, LLC. | $27.83 | 2019 | |
| Radius Health, INC. | $15.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.90 | 2019 | |
| Amarin Pharma, INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Holthus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.